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Abstract. Field effect or field cancerization denotes the
presence of molecular aberrations in structurally intact
cells residing in histologically normal tissues adjacent to
solid tumors. Currently, the etiology of prostate field‑effect
formation is unknown and there is a prominent lack of knowledge of the underlying cellular and molecular pathways.
We have previously identified an upregulated expression
of several protein factors representative of prostate field
effect, i.e., early growth response‑1 (EGR‑1), platelet‑derived
growth factor‑A (PDGF‑A), macrophage inhibitory cytokine‑1 (MIC‑1), and fatty acid synthase (FASN) in tissues
at a distance of 1 cm from the visible margin of intracapsule prostate adenocarcinomas. We have hypothesized that
the transcription factor EGR‑1 could be a key regulator of
prostate field‑effect formation by controlling the expression
of PDGF‑A, MIC‑1, and FASN. Taking advantage of our
extensive quantitative immunofluorescence data specific for
EGR‑1, PDGF‑A, MIC‑1, and FASN generated in disease‑free,
tumor‑adjacent, and cancerous human prostate tissues, we
chose comprehensive correlation as our major approach to test
this hypothesis. Despite the static nature and sample heterogeneity of association studies, we show here that sophisticated
data generation, such as by spectral image acquisition, linear
unmixing, and digital quantitative imaging, can provide
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meaningful indications of molecular regulations in a physiologically relevant in situ environment. Our data suggest that
EGR‑1 acts as a key regulator of prostate field effect through
induction of pro‑proliferative (PDGF‑A and FASN), and
suppression of pro‑apoptotic (MIC‑1) factors. These findings were corroborated by computational promoter analyses
and cell transfection experiments in non‑cancerous prostate
epithelial cells with ectopically induced and suppressed
EGR‑1 expression. Among several clinical applications, a
detailed knowledge of pathways of field effect may lead to
the development of targeted intervention strategies preventing
progression from pre‑malignancy to cancer.
Introduction
Several pre‑malignant states of prostate tissues have been
previously described to indicate the progression to prostate
adenocarcinoma (prostate cancer). Perhaps the most prominent
histological deviation from normalcy is prostatic intraepithelial neoplasia (PIN), which can manifest itself as a low‑ or
high‑grade form (1). All forms of PIN are characterized by
the presence of intraluminal proliferation of the secretory cells
of the duct acinar system and abnormal cytological features,
including the ratio of nuclear‑to‑cytoplasmic area, the size
of nucleoli, and the chromatin content (2). Another form of
pre‑malignancy is accepted to be proliferative inflammatory
atrophy (PIA), which constitutes a possible link between
inflammation and the malignant transformation of prostatic
tissues (3). PIA is mainly recognized in low‑magnification
microscopy by a distinct hyperchromatic appearance of glandular components and variable acinar calibers, and a marked
presence of inflammatory cells (4). Of note, both PIN and PIA
are histologically evident lesions that are identifiable by trained
surgical pathologists. However, it is reasonable to postulate that
cell morphological changes leading to histologically abnormal
appearances of prostate glands are preceded by molecular
alterations that occur in complete absence of any cytological
or histological change. This definition is in complete agreement with the concept of ʻfield effectʼ or ʻfield cancerizationʼ,
two terms that are used interchangeably in this report to reflect
contemporary research efforts. Originally introduced for
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renegade cancer cells outside the margins of squamous oral
cell carcinoma (5), the updated definition excludes cellular and
histological changes and focuses on molecular aberrations (6).
Thus, ʻfield‑cancerizedʼ prostate tissues have been recently
characterized by us and others (7‑10) by genetic, epigenetic,
and biochemical alterations in structurally intact epithelial
and stromal cells of histologically normal tissues adjacent to
prostate adenocarcinomas.
Along this line, we have recently described four protein
factors of prostate field effect. These include the key transcription factor early growth response‑1 (EGR‑1), the lipogenic
enzyme fatty acid synthase (FASN), and the secreted
growth factors platelet‑derived growth factor‑A (PDGF‑A)
and macrophage inhibitory cytokine‑1 (MIC‑1) (11‑13). Our
previous reports focused on emphasizing the similarity of the
expressions of these factors between tumor tissues and their
adjacent tissue areas, thereby supporting the concept of a field
effect. Field effect in the prostate has been recognized to be
of potential clinical value (7‑10), which ideally necessitates an
understanding of its underlying causative functional pathways.
Towards this goal, the specific purpose of the present study
was to explore a possible regulatory association between the
transcription factor EGR‑1 and the expression of PDGF‑A,
MIC‑1, and FASN. Our primary focus was the analysis of this
potential regulatory network by mining extensive datasets
consisting of expression levels of EGR‑1, PDGF‑A, MIC‑1,
and FASN, in human prostate tissues. Findings from these
analyses were corroborated by ectopic control of EGR‑1 and
its effect on PDGF‑A, MIC‑1, and FASN expression in the
non‑cancerous RWPE‑1 human prostate epithelial cell model.
Accordingly, our data indicate that the key transcription factor
EGR‑1 positively regulates PDGF‑A and FASN, and negatively
regulates MIC‑1. These associations provide novel insight
into the pathways underlying prostate field effect, which may
lead to the development of targeted intervention strategies
preventing progression from pre‑malignancy to cancer.
Materials and methods
Tissues. The tissue cohort utilized in the present study represents a combination of the cohorts reported in our previous
studies on prostate field effect (12,13). These tissues were
collected in agreement with all Federal, State, and University
laws, from consenting patients undergoing prostatectomy
and donating ~100‑500 mg of remnant tissue for molecular
analyses. Individual cases of de‑identified disease‑free
tissue samples were obtained from the Cooperative Human
Tissue Network (CHTN) supported by the National
Institutes of Health (NIH; Vanderbilt University, Nashville,
TN, USA). All tissues were available as formalin‑fixed
and paraffin‑embedded (FFPE) sections of 5‑µm thickness [processed by the Department of Pathology, University
of New Mexico Health Sciences Center (Albuquerque, NM,
USA) or provided by CHTN]. The study was approved by the
Institutional Review Board of the University of New Mexico
Health Sciences Center specifically approved the present study
(#05‑417). The combined tissue cohort consisted of 14 adenocarcinomas, 16 tumor‑adjacent tissues, and 9 disease‑free
tissues. Twelve tumor‑adjacent and tumor tissues were
matched; for the missing unmatched tissues, the quality of

data was insufficient for inclusion into the final results. The
definition of the term ʻtumor‑adjacentʼ in our studies refers
to tissue resected at a distance of ~1 cm from the visible
tumor margin. The definition of the term ʻdisease‑freeʼ refers
to prostate specimens from autopsy cases from individuals
who died due to conditions unrelated to cancer. All tissues
had been histologically reviewed previously by the surgical
pathologist E.G. Fischer (Department of Pathology, University
of New Mexico Health Sciences Center), especially to exclude
the presence of cryptic cancer cells in the tumor‑adjacent
prostate tissues (12,13). The mean age of all cases utilized
was 56.1 years with a range of 26‑79 years. The cancer
specimens featured Gleason scores from 6 to 9 and pathological tumor node metastasis (TNM) stages (according to the
American Joint Committee on Cancer; https://cancerstaging.
org/Pages/default.aspx) from T2c to T3b (Table I).
Quantitative immunofluorescence. The generation of quanti
tative immunofluorescence data was reported in our previous
studies on prostate field effect (12,13). These procedures
included deparaffinization, antigen retrieval, and immunostaining using specific primary antibodies and Alexa
Fluor 633‑conjugated secondary antibodies. For reference
purposes, we list here the specific reagents, while the experimental details have been described (12,13). The primary
antibodies were: anti‑EGR‑1 mouse monoclonal antibody
ab54966 (at 3 µg/ml); anti‑MIC‑1 goat polyclonal antibody
ab39999 (at 3 µg/ml) (both from Abcam, Cambridge, MA,
USA); anti‑PDGF‑A rabbit polyclonal antibody sc‑7958 (at
3 µg/ml); and anti‑FASN rabbit polyclonal antibody sc20140
(H‑300) (at 8 µg/ml) (both from Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA). The corresponding control
antibodies to ensure target specificity at the same concentrations were: normal mouse IgG (GC270; EMD Millipore,
Billerica, MA, USA), normal rabbit IgG (10500C), and
normal goat IgG (10200) (both from Invitrogen, Carlsbad,
CA, USA). The corresponding secondary antibodies were
Alexa Fluor 633‑conjugated goat anti‑mouse IgG, Alexa
Fluor 633‑conjugated goat anti‑rabbit IgG, and Alexa
Fluor‑conjugated rabbit anti‑goat IgG (A21052, A21070,
A21086, respectively; all from Invitrogen). Nuclear
counterstaining was performed with 4',6-diamidino-2-phenylindole (DAPI).
Quantitative assessment of fluorescence was by spectral
image acquisition and linear unmixing modes of confocal
microscopy performed at the University of New Mexico Health
Sciences Center, Fluorescence Microscopy Shared Resource
Core Facility, as described previously by us (12,13). Of note,
control tissue slides with DAPI only, secondary antibody only,
as well as unstained tissue were imaged separately to generate
specific emission spectra for nuclear staining (DAPI; 405 nm
excitation, 433 nm emission), Alexa Fluor (633 nm excitation,
490 nm emission), and background autofluorescence (ditto as
per Alexa Fluor), respectively. These spectra were subjected
to linear unmixing, a process that was equally applied to
all spectral images to ensure the validity of inter‑tissue
comparisons. Consistent with our previous studies (12,13),
quantification was achieved by digital imaging of the spectrally unmixed confocal images using two data acquisition
modes. i) Whole‑image analysis: the total Alexa Fluor 633
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Table I. Demographics and clinical parameters of prostate tissues, and number of images analyzed.a
		
No. of images analyzedc
Age	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑-----------------------------------------------------------------‑‑‑‑
Prostate tissues
(years)
TNMb
Gleason
EGR‑1
MIC‑1
PDGF‑A
FASN
Disease‑free
(CHTN)
1
26
Not applicable
Not applicable
2
43
Not applicable
Not applicable
3
46
Not applicable
Not applicable
4
79
Not applicable
Not applicable
5
43
Not applicable
Not applicable
6
55
Not applicable
Not applicable
7
55
Not applicable
Not applicable
8
45
Not applicable
Not applicable
9
n/ad
Not applicable
Not applicable
Total				

3
3	‑‑	
3
3
3	‑‑	
3
3	‑‑	
3
4
3
4
2	‑‑
3
3
3
4
3
3
2
4
3	‑‑	‑‑	
4
3	‑‑	‑‑	
3
3	‑‑	‑‑	‑‑
27
16
10
25

		
Tumor
Adjacent
Age	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑--------------------------------------‑‑‑‑‑‑‑‑‑‑‑‑‑‑	‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑----------------------------------------‑‑‑‑‑‑‑‑‑‑‑‑
Prostate tissues
(years) TNMb
Gleason EGR‑1 MIC‑1 PDGF‑A
FASN
EGR‑1 MIC‑1 PDGF‑A
FASN
Tumor and adjacent
(UNMH/CHTN)e
1
51
n/ad
7 (3+4)	‑‑	
3	‑‑	‑‑	‑‑	‑‑	‑‑	‑‑
2
54
T3a
7 (3+4)	‑‑	
3	‑‑	‑‑	‑‑	‑‑	‑‑	‑‑
3 (m)
59
T3b
9 (4+5),
3
3
3
3
3
3
3
3
			
6 (3+3)								
4 (m)
63
T3a
6 (4+3)	‑‑	
5
2	‑‑	‑‑	
3
3	‑‑
5 (m)
69
T2c
7 (4+3)
3
3
6
3
6
3
3
3
6 (m)
68
T3b
8 (5+3)
3
4
3
3
3
3
3
3
7 (m)
55
T2c
8 (3+5)
3
6
9	‑‑	
6
6	‑‑	‑‑
8 (m)
57
T3a
7 (4+3)
3
3
3
3
3
3
3
3
9 (m)
55
T2c
8 (3+5)
3	‑‑	
3
3
6	‑‑	
3
9
10 (m)
54
T2‑T3
6 (3+3)	‑‑	‑‑	‑‑	
3
6	‑‑	
6
6
11
54
T2c
6 (3+3)	‑‑	‑‑	‑‑	‑‑	
9	‑‑	
5
9
12 (m)
64
T3b
6 (3+3)
3	‑‑	
4	‑‑	
9	‑‑	
4	‑‑
13
62
T2c
6 (3+3)	‑‑	‑‑	‑‑	‑‑	
9
9
9
16
14 (m)
62
T3b
7 (4+3)
3
4
3
4
6
5
3
9
15 (m)
44
T2c
6 (3+3)
3	‑‑	
3
4
5	‑‑	‑‑	
6
16
58
T2c
9 (4+5)	‑‑	‑‑	‑‑	‑‑	
9	‑‑	‑‑	
10
17
69
T2c
6 (3+3)	‑‑	‑‑	‑‑	‑‑	
9	‑‑	‑‑	
12
18 (m)
68
T3a
7 (3+4)
3
3
3
4
3
6	‑‑	
4
Total				 30
37
42
30
92
41
45
93
A total of 14 adenocarcinomas (tumor), 16 tumor‑adjacent tissues (adjacent), and 9 disease‑free tissues were analyzed. In total, 488 images were queried
(numbers for each case and marker are indicated). Specimens were collected at the University of New Mexico Hospital (UNMH; Albuquerque, NM, USA) or
obtained from the CHTN. bTNM pathological stage was assigned using criteria published by the American Joint Committee on Cancer (https://cancerstaging.
org/Pages/default.aspx). c‑‑, indicates no available images of sufficient quality. dn/a, not available. e(m), indicates tumors that were matched with their corresponding adjacent tissues. CHTN, Cooperative Human Tissue Network; TNM, tumor node metastasis; EGR‑1, early growth response‑1; MIC‑1, macrophage
inhibitory cytokine‑1; PDGF‑A, platelet‑derived growth factor‑A; FASN, fatty acid synthase.
a

signal was ratio‑normalized to the total DAPI signal to account
for the number of cells and the cell density per slide, which
tends to be different between cancerous and non‑cancerous
tissues. For EGR‑1, the whole‑image data acquisition mode

was applied in three settings, i.e., whole‑cell (no selection),
nuclear selection, and cytoplasmic selection, according to its
ability to translocate between the two cell compartments (14).
ii) Region of interest (ROI) analysis: three representative ROIs
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(defined as areas with robust immunostaining) per slide were
chosen and the cumulative signal specific for Alexa Fluor 633
was determined. The ROI acquisition mode was applied to
all factors according to their typical expression, i.e., both
nuclear and cytoplasmic for EGR‑1, extranuclear for MIC‑1
and PDGF‑A, and cytoplasmic for FASN. The size of ROI
was identical from image to image (~80 µm2 each) and they
were chosen by persons blinded to the nature of the tissue
(Mrs. Virginia Severns, Ms. Fiona Bisoffi, Ms. Suzanne Jones)
to avoid bias (Fig. 1B). All original red signals were converted
to yellow for better visibility. In total, 488 images with associated quantitative immunofluorescence data were available for
the present analysis (Table I).
Computational transcription factor binding site analysis.
Computational searches for a potential transcription factor
binding site were performed using the Tfsitescan software
of the Molecular Informatics Resource for the Analysis
of Gene Expression (MIRAGE) provided by the Institute
for Transcriptional Informatics (IFTI; http://www.ifti.
org/cgi-bin/ifti/Tfsitescan.pl). Genomic sequences for EGR‑1,
PDGF‑A, MIC‑1, and FASN were retrieved from the GRCh38
primary assembly of the gene database available at the National
Center for Biotechnology Information (NCBI; http://www.ncbi.
nlm.nih.gov/). The specific reference sequences and locations
were: NC_000005.10, Homo sapiens chromosome 5, location
138,465,492‑138,469,315 for EGR‑1; NC_000019.10, Homo
sapiens chromosome 19, location 18,386,158‑18,389,176 for
MIC‑1; NC_000007.14, Homo sapiens chromosome 7, location 497,258‑520,123 for PDGF‑A; and NC_000017.11, Homo
sapiens chromosome 17, location 82,078,338‑82,098,230 for
FASN. The genomic sequences were subjected to searches for
the EGR‑1 recognition sequence [GCG(G/T)GGCG] (15).
Cell culture and transfections. Non‑cancerous RWPE‑1 human
prostate epithelial cells were purchased from the American
Type Culture Collection (Manassas, VA, USA) and cultured in
serum‑free keratinocyte basal medium containing 4,500 mg/l
glucose, 0.05 mg/ml bovine pituitary extract and 5 ng/ml
recombinant epidermal growth factor (Invitrogen). Cells were
maintained at 37˚C in a humidified 5% CO2 atmosphere.
Trypsin‑EDTA at 0.25% was used to detach the cells for splitting and reculturing. pcDNA3.1 control and pcDNA3.1/EGR‑1
plasmids were a kind gift of Dr W. Xiao (University of Science
and Technology of China, Hefei, China). pLKO.1 control and
pLKO.1/EGR‑1 shRNA plasmids were from Sigma (St. Louis,
MO, USA). Plasmids were propagated in E. coli strain JM109
grown in LB broth containing 100 µg/ml ampicillin and
purified using spin column chromatography (Qiagen, Inc.,
Valencia, CA, USA). Transfections were performed with 1 µg
plasmid DNA in 24‑well plates containing 150,000 cells/well
using Lipofectamine 2000 reagent (Invitrogen) for 48 h. Our
transfection protocol yields reproducible transfection rates
of 45±5% for pairs of empty control and cDNA‑carrying
plasmids (fluorescence‑based assay, not shown). Cells were
snap‑frozen in liquid nitrogen to preserve RNA integrity and
stored short-term at ‑80˚C.
Quantitative reverse transcriptase‑polymerase chain reac‑
tion (qRT‑PCR) and western blotting. RNA was isolated using

spin column chromatography (Qiagen, Inc.). A total of 1‑3 µg
of RNA was transcribed to cDNA using random decamers of
the Retroscript™ RT Kit (Ambion/Life Technologies,
Carlsbad, CA, USA). mRNA expression was quantitated in a
CFX Connect Real‑Time PCR Detection System from
Bio‑Rad (Hercules, CA, USA) using the SYBR‑Green PCR
Master Mix and SYBR‑Green RT‑PCR Reagents Kit (Applied
Biosystems/Life Technologies, Carlsbad, CA, USA) in 25‑µl
reactions, using 100 ng of template cDNA and a final primer
concentration of 900 nM. The cycling parameters were 95˚C
for 5 min followed by 45 cycles of 94˚C for 15 sec, and 51‑58˚C
for 1 min. Primers were designed using Primer Express software (Invitrogen) and synthesized by Integrated DNA
Technologies (Coralville, IA, USA). The following primer
sequences (5'→3') were used: EGR‑1 forward, GAGCAG
CCCTACGAGCAC and reverse, AGCGGCCAGTATAGG
TGATG; MIC‑1 forward, CTACAATCCCATGGTGCTCAT
and reverse, TCATATGCAGTGGCAGTCTTT; PDGF‑A
forward, CGTAGGGAGTGAGGATTCTTT and reverse,
GCTTCCTCGATGCTTCTCTT; FASN forward, AGAACT
TGCAGGAGTTCTGGGACA and reverse, TCCGAAGAA
GGAGGCATCAAACCT; TATA‑binding protein (TBP)
forward, CACGAACCACGGCACTGATT and reverse, TTT
TCTTGCTGCCAGTCTGGAC. qRT‑PCR reactions were
performed in triplicate. Relative expression levels were determined by the ΔΔCt method using TBP as normalization
control after determining that amplification efficiencies were
similar to the ones of the control transcripts.
Protein lysates were generated on ice in lysis buffer:
25 mM Tris, 8 mM MgCl2, 1 mM DTT, 15% glycerol, 1%
Triton X‑100, protease inhibitor cocktail (Sigma). Insoluble
cell material was removed by centrifugation of lysates at
13,000 rpm for 10 min at 4˚C. The protein concentration
was determined by Bradford assay (Sigma) against a bovine
serum albumin (BSA) standard. Total protein (80 µg) was
size‑separated by sodium dodecyl sulfate‑polyacrylamide
gel electrophoresis (SDS‑PAGE), electro‑blotted onto polyvinylidene fluoride (PVDF) membranes, blocked with 5% milk
powder in Tris‑buffered saline, and probed overnight with
anti‑EGR‑1 and anti‑β‑actin primary antibodies (sc‑189 from
Santa Cruz Biotechnology, Inc., Dallas, TX, USA and A1978
from Sigma, respectively). Detection and chemiluminescent
visualization (Clarity ECL substrate; Bio‑Rad) of EGR‑1
and β ‑actin were performed using host‑matched secondary
horseradish peroxidase‑conjugated antibodies (Sigma). The
quantitative signal intensity of bands was determined by densitometry using ImageJ software (https://imagej.nih.gov/ij/).
Statistics. EGR‑1, PDGF‑A, MIC‑1, and FASN expression
levels were represented by signal intensities (sum pixel count
per area) generated by quantitative immunofluorescence
analysis (as described above). Straightforward, yet robust
statistical methods were applied to the datasets using the
Microsoft Excel software package (Microsoft, Redmond, WA,
USA). The datasets were inclusive (all available informative
images), for matched cases only, or separated by the means.
These approaches are indicated in the ‘Results’ section.
Correlations between the expressions of EGR‑1 and
PDGF‑A, MIC‑1, and FASN were analyzed by several statistical
methods. To control for small sample size and a distribution
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Figure 1. (A) Representative detection of EGR‑1, PDGF‑A, MIC‑1, and FASN by immunofluorescence in tumor (panels i‑ⅳ), tumor‑adjacent (panels v‑ⅷ), and
disease‑free (panels ⅸ‑ⅻ) human prostate tissues. Unspecific IgG of mouse, rabbit, and goat origin were tested for absence of staining (panels xⅲ‑xv). Images
represent Alexa Fluor 633 immunostaining (yellow signals); the smaller insets represent corresponding nuclear staining by DAPI (blue); white bars, 10 µm.
(B) Schematic representation of the whole‑image (top) and ROI (bottom) quantitative acquisition modes for EGR‑1 fluorescence intensity. Whole‑image data
acquisition includes three different settings as defined by DAPI staining, whole‑cell/no selection (panel i), nuclear (panel ⅱ), and cytoplasmic (panel iii),
as indicated by the bright blue shading. ROI data acquisition includes nuclear (panel ⅳ) and extranuclear/cytoplasmic (panel v), as indicated by the areas
designated by the randomly placed yellow rectangle frames (~80 µm 2); white bars, 10 µm. EGR‑1, early growth response‑1; PDGF‑A, platelet‑derived growth
factor‑A; MIC‑1, macrophage inhibitory cytokine‑1; FASN, fatty acid synthase; ROI, region of interest.
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Figure 2. (A and B) Ratios of PDGF‑A, MIC‑1, and FASN to EGR‑1 expression (combined whole-cell, nuclear, cytoplasmic) in disease‑free (DF), tumor‑adjacent (ADJ), and tumor (TUM) tissues using images from all (left three bars) and matched only (right three bars) cases, acquired by the whole‑image and the
ROI mode, respectively. The bars represent average ratios + standard errors. The numbers by the bars represent the fold change in ADJ and TUM compared
to DF tissues. *Statistical significance compared to DF tissues (p≤0.05). PDGF‑A, platelet‑derived growth factor‑A; MIC‑1, macrophage inhibitory cytokine‑1;
FASN, fatty acid synthase; EGR‑1, early growth response‑1; ROI, region of interest.

with infinite variance due to tissue heterogeneity (expressed as
coefficient of variation in %; reported in the text of ʻResultsʼ),
the Wilcoxon rank‑sum test (as opposed to the Student's t‑test)
was used for pairs of datasets (reported in the text of ʻResultsʼ).
The single factor analysis of variance (ANOVA) was applied
for comparisons of multiple datasets with unequal variances.
Statistical significance for the change of ratios of PDGF‑A,
MIC‑1, or FASN to EGR‑1 in tumor‑adjacent and tumor
tissues as compared to disease‑free tissues was determined by
the two‑tailed Student's t‑test (statistical significance defined
as p≤0.05; Fig. 2A and B). The datasets were further mined
for potential associations between factors by determining the
Pearson's correlation coefficient (r). The significance for these
observations was determined by first calculating the t‑value
of the correlation using the equation t = r/SQRT[(1 ‑ r2)/(n‑2)],
where r is the correlation coefficient, n is the number of
samples, and n-2 is the degree of freedom. The t‑value was
then used to determine the significance of r by the two‑tailed
Student's t‑distribution (TDIST; statistical significance defined
as p≤0.05; reported in the text, but not shown). Statistical
significance for the change of ratios of positive to negative

Pearson's correlations of PDGF‑A, MIC‑1, and FASN to
EGR‑1 in tumor‑adjacent and tumor tissues as compared to
disease‑free tissues was determined by the F‑test with p≤0.05
considered to be significant (Fig. 3B and D).
Results
Immunofluorescence detection of EGR‑1, PDGF‑A, MIC‑1,
and FASN in human prostate tissues. We previously reported
on the extent of the individual expression of EGR‑1, PDGF‑A,
MIC‑1, and FASN to support the concept of field effect in histologically normal prostate tissues adjacent to histologically overt
adenocarcinomas, as compared to disease‑free tissues (12,13).
To begin unraveling the functional pathways of field effect in
prostate tissues, here we analyzed the potential association
between these markers of field effect in human prostate tissues
of different histology. For this analysis, a total of 488 digitized
images from 39 individual human prostate tissue samples was
available for a comprehensive analysis (Table I). The images
indicate the specific detection of EGR‑1, PDGF‑A, MIC‑1,
and FASN by immunofluorescence which was quantified
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Figure 3. (A and C) Graphical representation of Pearson's correlation (r) between EGR‑1 and PDGF‑A, MIC‑1, and FASN using data from digitized images
acquired by the whole‑image and the ROI mode, respectively. Within each type of tissue, disease‑free (DF), tumor‑adjacent (ADJ), and tumor (TUM), correlations were determined for all matched, and for EGR‑1 above or below the median with the corresponding median‑divided datasets of PDGF‑A, MIC‑1, and
FASN. (A) Datasets consist of whole‑cell, nuclear, and cytoplasmic EGR‑1 measurements (a total of 15 correlations per factor). (B) Datasets consist of nuclear
and cytoplasmic EGR‑1 measurements (a total of 12 correlations per factor). Arrows depict the change of regulation by linking the mean Pearson's correlations
(black dots) in the different types of tissues. (B and D) Average positive (pos; black bars) and negative (neg; grey bars) Pearson's correlations between EGR‑1
and PDGF‑A, MIC‑1, and FASN in DF, ADJ, and TUM tissues acquired by the whole‑image and the ROI mode, respectively. The bars represent average
ratios + standard errors. The numbers represent the fold change in the ratio of positive/negative r in ADJ and TUM compared to DF tissues. *Statistical
significance compared to DF tissues (p≤0.05). EGR‑1, early growth response‑1; PDGF‑A, platelet‑derived growth factor‑A; MIC‑1, macrophage inhibitory
cytokine‑1; FASN, fatty acid synthase; ROI, region of interest.

computationally (12,13). Representative images are shown
in Fig. 1A. In general, the expressions of EGR‑1, PDGF‑A,
MIC‑1, and FASN were highest in tumor and lowest or absent
in disease‑free tissues (Fig. 1A, panels i‑ⅳ and ⅸ‑ⅻ, respectively). Furthermore, tumor‑adjacent tissues tended to display
elevated expression of all factors (Fig. 1A, panels v‑ⅷ).
The specificity of detection was corroborated by the absent
staining with isotype‑specific control antibodies (Fig. 1A,
panels xⅲ‑xv).
Quantification and association analyses of EGR‑1, PDGF‑A,
MIC‑1, and FASN expressions in human prostate tissues. We
have previously developed sensitive quantification methods

for signals generated by immunofluorescence in human
prostate tissues [(12,13) and the ʻMaterials and methodsʼ].
These methods include whole‑image and ROI data acquisition
modalities for all investigated factors (in the ʻMaterials and
methodsʼ). Furthermore, in line with the aim of this study to
be as comprehensive as possible with respect to associative
analyses, EGR‑1 expression was measured using three specific
settings for cell compartmentalization: whole-cell, as well as
nuclear and cytoplasmic separately. This is supported by an
elegant study by Mora et al (14) who showed that EGR‑1 can
shuttle between these locations depending on cellular type and
context. These different types of data acquisition are shown
in Fig. 1B.
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While our previous reports compared the level of expression for EGR‑1, PDGF‑A, MIC‑1, and FASN in disease‑free,
tumor‑adjacent, and tumor tissues, thereby supporting the
concept of field effect (12,13), the primary objective of the
present study was to explore a potential relationship between
these factors and to determine whether that relationship
changes in different types of tissues. As expected, and typical
for human tissue studies, both the whole‑image and the ROI
data acquisition modes resulted in substantial heterogeneity
with respect to variation of expression of all factors in
disease‑free, tumor‑adjacent, and tumor tissues. The coefficient
of variations ranged from 4.7 to 39.0% in the whole‑image and
from 3.9 to 31.1% in the ROI measurements.
Quantified expression data were comprehensively analyzed
for similarities, discrepancies, and associations using straightforward, yet robust statistical methods. Of note, because of the
expected inter‑ and intra‑tissue heterogeneity, the identification
of outliers was not meaningful and we adopted an inclusive
approach in which we did not exclude any data points. In
addition, due to different antibody affinities for their targets,
we determined that comparisons of the mean, variance, and
distribution of expression data between factors would not be
good indicators of a causative regulatory role of EGR‑1 for the
other factors. In fact, group analysis by ANOVA indicated that
all expression patterns in all types of tissues were distinct from
each other (p<0.001), and individual comparisons by Wilcoxon
rank‑sum test were non‑informative with respect to the distinction between induction and repression (p≤0.05) or coupled
expression (p>0.05). Consequently, we chose to analyze the
change of the ratio of either PDGF‑A, MIC‑1, or FASN to EGR‑1
in disease‑free compared to tumor‑adjacent and tumor tissues.
Based on our previous results showing that prostate tissues
adjacent to adenocarcinomas feature a field effect compared
to disease‑free tissues (12,13), such a change in ratio would
suggest a potential regulatory role of EGR‑1 in agreement
with its proven upregulation during tumorigenesis and cancer
progression (16). Accordingly, EGR‑1 expression determined
by both the whole‑image and ROI acquisition modes in all
available tissues revealed an increase of all factors‑to‑EGR‑1
ratios, up to 2.5‑fold for PDGF‑A, 16.9‑fold for MIC‑1, and
2.8‑fold for FASN (Fig. 2A and B, left bar graphs). Similarly,
when analyzed for matched adjacent and tumor tissues only
(derived from the same patients, respectively), the ratio of the
other factors to EGR‑1 in both acquisition modes markedly
increased, up to 136.4‑fold for PDGF‑A, 273.8‑fold for MIC‑1,
and 2.5‑fold for FASN (Fig. 2A and B, right bar graphs). While
this analysis does not reveal the direction of regulation (positive or negative), the changes do indicate a regulatory function
of EGR‑1 for PDGF‑A, MIC‑1, and to a lesser extent for FASN.
The changes in the expression ratio of PDGF‑A, MIC‑1,
and to some extent FASN, prompted us to refine our determination of a potential regulatory effect of EGR‑1 on these
factors by using Pearson's correlation analysis, which is independent of differences in antibody affinities for the different
factors. By definition, this approach included tissues from
matched cases only. To refine our analysis, we also separated
all expression data by the median and determined the correlation between expression levels above and below median
values. Similar to the ratio analysis presented in Fig. 2, we
attempted to corroborate possible regulatory effects of EGR‑1

for PDGF‑A, MIC‑1, and FASN expressions by comparing
Pearson's correlations between different types of tissues, i.e.,
disease‑free, tumor‑adjacent, and tumor tissues. Fig. 3A and C
shows a graphical representation of all possible correlations
between whole‑cell, nuclear, and cytoplasmic EGR‑1 and
PDGF‑A, MIC‑1, and FASN expression in disease‑free,
tumor‑adjacent, and tumor tissues as acquired by whole‑image
and ROI acquisition mode, respectively. In contrast to group
analyses by ANOVA or individual comparisons by Wilcoxon
rank‑sum test, Pearson's correlation analyses are indicators of
positive vs. negative regulation. The significance (average p)
of the Pearson's correlation coefficients for the whole‑image
acquisition mode was 0.16, 0.24, and 0.25 (with 40, 7 and 18%
of all coefficients being p≤0.05) for PDGF‑A, MIC‑1, and
FASN, respectively. For the ROI acquisition mode, the
significance (average p) for the corresponding factors was
0.21, 0.21, and 0.25 (with 17, 23 and 7% of all coefficients
being p≤0.05). Visual inspection of the Pearson's correlation
analyses in Fig. 3A and C indicates that EGR‑1 positively
and negatively regulates PDGF‑A and MIC‑1, respectively,
while the results for FASN regulation were less clear due
to the contrasting data between the two data acquisition
modes. Similar to the ratio analysis presented in Fig. 2, we
attempted to corroborate possible regulatory effects of EGR‑1
for PDGF‑A, MIC‑1, and FASN expressions by comparing
Pearson's correlations between different types of tissues, i.e.,
disease‑free, tumor‑adjacent, and tumor tissues. Given the
high tissue heterogeneity, we used an inclusive approach and
compared the average of all positive and negative correlations
(r>0 or <0) for each factor in the three types of tissues. This
analysis showed a progressive positive and negative regulation of PDGF‑A (up to 64.6‑fold) and MIC‑1 (up to 10‑fold),
respectively, in tumor‑adjacent and tumor tissues compared
to disease‑free tissues. Again, results for FASN were less
clear with contrasting results depending on the data acquisition mode (Fig. 3B and D). These possible regulations were
confirmed by visually linking the means of Pearson's correlations in the different types of tissues (Fig. 3A and B).
Computational and cell experimental analysis of EGR‑1
regulation of PDGF‑A, MIC‑1, and FASN. The theoretical
potential of the transcription factor EGR‑1 to be a regulator
of PDGF‑A, MIC‑1, and FASN expression was determined
computationally using Tfsitescan software applied to 1,500 bp
upstream and 500 bp downstream of the transcription initiation site on the genomic sequences of PDGF‑A, MIC‑1, and
FASN. Thus, a total of 2,000 bp was screened for the presence
of the EGR‑1 recognition sequence [GCG(G/T)GGCG] (15).
This analysis resulted in the identification of two, one, and
four recognition sequences for PDGF‑A, MIC‑1, and FASN,
respectively (Fig. 4A). Regulation of PDGF‑A, MIC‑1, and
FASN expression by EGR‑1 was experimentally tested
by overexpression and suppression of EGR‑1 in transient
transfection experiments using the non‑cancerous RWPE‑1
human prostate epithelial cell model. The immortalized but
non‑cancerous RWPE‑1 cells were chosen because they best
represent the tissues analyzed in this study, which are almost
exclusively early‑stage malignancy and tumor‑adjacent, i.e.,
best reflective of field effect. Transfections with the pcDNA3.1
and the pLKO.1 plasmids typically resulted in 50‑100‑fold
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Figure 4. (A) Computational analysis of the EGR‑1 recognition sequence [GCG(G/T)GGCG] in the genomic sequence 1,500 bp upstream and 500 bp downstream of the transcription initiation site of PDGF‑A, MIC‑1, and FASN. Black vertical lines and black rectangular boxes denote genomic sequences and
exons, respectively; vertical arrow heads indicate EGR‑1 recognition sequences. (B) EGR‑1, PDGF‑A, MIC‑1, and FASN protein expression in RWPE‑1 cells
transiently transfected with pcDNA3.1/EGR‑1 (EGR‑1 overexpression) or pLKO.1/EGR‑1 shRNA (EGR‑1 suppression), and their empty plasmid controls.
Double bands in EGR‑1 represent post‑translational modifications (44). The fold change difference compared to empty plasmid control and determined by
densitometry as a ratio with β‑actin signal is indicated in the small bar graphs (left bar, EGR‑1 overexpression; right bar, EGR‑1 suppression). (C) Relative
mRNA expression of PDGF‑A, MIC‑1, and FASN in RWPE‑1 cells transiently transfected with pcDNA3.1/EGR‑1 (EGR‑1 overexpression) or pLKO.1/EGR‑1
shRNA (EGR‑1 suppression), and their empty plasmid controls. Bars represent averages of triplicates ± standard deviation; *Statistical significance (p≤0.05)
from pcDNA3.1 and pLKO.1 plasmid vector control, respectively. EGR‑1, early growth response‑1; PDGF‑A, platelet‑derived growth factor‑A; MIC‑1, macrophage inhibitory cytokine‑1; FASN, fatty acid synthase.

overexpression and suppression of EGR‑1 at the mRNA level
(not shown). Modulation of EGR‑1 protein expression was

ver ified by western blotting and resulted in ~2‑fold overexpression and suppression. Although the regulatory effects
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on PDGF‑A, MIC‑1, and FASN were rather small, transient
EGR‑1 overexpression upregulated PDGF‑A and FASN
protein expression (up to 2‑fold) and downregulated MIC‑1
protein expression (up to 3‑fold), while transient EGR‑1
suppression corroborated this effect by upregulating MIC‑1
protein expression (~1.5‑fold), while downregulating PDGF‑A
and FASN protein expression (up to 2‑fold) (Fig. 4B). These
results were accompanied by similar changes at the mRNA
level, as measured by qRT‑PCR. Accordingly, transient EGR‑1
overexpression upregulated PDGF‑A and FASN (up to 2‑fold)
and downregulated MIC‑1 (up to 2‑fold), while transient
EGR‑1 suppression corroborated this effect by downregulating PDGF‑A and FASN (up to 2.5‑ and 5‑fold, respectively)
and by upregulating MIC‑1 (up to 10‑fold) (Fig. 4C). Overall,
these results are in good agreement with the observations
made in the tissues.
Discussion
The importance of field effect, or field cancerization, in
the prostate has been well‑recognized as worthy of being
explored in detail for the benefit of developing clinical applications towards a better clinical management of prostate
cancer (8‑10,17). For example, we have previously argued that
prostate field effect could be used to improve the diagnosis
of prostate cancer in false‑negative biopsies (10). The latter
remains an important and continuous challenge in confirmatory diagnosis of prostate adenocarcinoma that has clinical,
psychological, and financial implications (18‑21). Accordingly,
field‑cancerized tissue could increase the clinically informative area that can be analyzed microscopically by a surgical
pathologist if histology could be combined with immunological
techniques. In this scenario, the pathologist would recognize
the presence and location of a lesion even in the absence of its
visual confirmation thereby avoiding false‑negative cells, even
after repeated biopsies (22). This possibility has prompted
others to term tissues affected by field‑effect tumor‑indicating
normal tissue (TINT) (8). Even in the case of a positive
identification of cancer, the extent (number of positive biopsy
cores, % of tissue affected) and the grade (Gleason) may indicate a low risk for progression and thus eligibility for active
surveillance with frequent testing for serum prostate‑specific
antigen (PSA), as opposed to prostatectomy (23). It is conceivable that during active surveillance, a recognized field effect
could be monitored and queried as an indicator of potential
progression (10,24). This would help mitigate the well‑known
overtreatment of prostate cancer with surgery, which albeit
performed with curative intent, may unnecessarily decrease
quality of life due to its severe side‑effects (25,26). The
latter approach could also be amenable to the assessment of
pre‑surgical neo‑adjuvant therapeutic interventions, for which
the efficacy could be monitored during active surveillance by
established markers and parameters of field effect (10,27). A
further potential application of field effect lies in its inclusion
in the definition of surgical margins for focal therapy, which
seems to be on the rise as a form of less invasive therapy
and as more refined interventions have developed (10,28,29).
As such, the presence of a field effect at the margin may be
indicative of elevated risk for progression or of the extent of
tumor multifocality within the prostate (10,30). Of note, the

common assumption underlying the aforementioned potential
applications of prostate field effect is that a field exists as a
consequence of the presence of a lesion. However, it is also
conceivable that field effect precedes tumor formation and
represents a truly pre‑malignant status evident at the molecular
level but in absence of any histological change. In fact, the latter
view is widely accepted (8‑10,17) and defines field‑cancerized
prostate tissues as a temporal record of tumorigenesis. As
such, it is a source for early biomarkers and potential targets
for preventative strategies (8,10).
Pertinent to all applications of field effect is the knowledge
of the molecular markers and pathways that are characteristic
for it. We and others have previously compiled lists of molecular markers reported in the scientific literature (7‑10), but
for most of these factors the etiology remains unknown. For
markers of field effect to be of best use, either as indicators or
as targets, it is important to begin identifying distinct cellular
and molecular events and pathways that underlie the formation
of a field. Towards this goal, in this report we have established
a link between four protein factors of prostate field effect,
which were originally identified individually or deduced from
the literature. We had identified the key transcription factor
EGR‑1, the divergent member of the transforming growth
factor‑β (TGF‑β) MIC‑1, and the lipogenic oncogene FASN as
being elevated in prostate tissues 1 cm from the visible tumor
margin (11). While our original study was microarray‑based
and thus RNA‑specific, we subsequently confirmed EGR‑1,
MIC‑1, FASN, and PDGF‑A protein upregulation in field‑can
cerized human prostate tissues (12,13).
EGR‑1 is a central regulator of many molecular pathways and acts divergently according to the cell context (31).
While in other types of tissues, it may function primarily as
a tumor suppressor, it ultimately assumes, with some ambiguity, a tumor‑promoting role in prostate cancer development
and progression (16,32,33). The role of the secreted factor
PDGF‑A in prostate cancer is well‑established. It is one of four
isoforms that binds as a dimer to the tyrosine kinase receptors PDGFRα and β. PDGF‑A stimulates growth, survival,
and motility of various cell types and when hyperactivated,
promotes prostate cancer development and progression
through paracrine and autocrine actions (34,35). Equally
established in prostate cancer development and progression is
FASN, which has been termed a metabolic oncogene and is the
target of ongoing efforts to develop specific inhibitors of its
lipogenic activity promoting tumor cell proliferation through
lipid biosynthesis and post‑translational protein modification (36,37). The role of MIC‑1 is less clear and is reported
as both a cancer promoter and suppressor (38,39). Originally
discovered in macrophages (40), it may promote a pro‑tumorigenic environment when secreted by prostate cancer cells by
suppressing the anticancer activity of immune cells (41).
It is conceivable that the concerted actions of MIC‑1,
PDGF‑A, and FASN can lead to the formation of molecularly
altered fields through autocrine stimulation of hyperproliferative cell foci prone to further genetic and biochemical change
towards transformation, which is congruent with the definition
of a pre‑malignant field effect. However, the possibility of
cross‑regulatory influences of these actions remain unknown.
Since EGR‑1 is a pleiotropic transcription factor, we hypothesized that it could regulate MIC‑1, PDGF‑A, and FASN.
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The present study aimed at testing this possibility through
comprehensive association analyses using quantitative immunofluorescence expression data generated in human prostate
tissues. EGR‑1 has been previously shown to induce many
target genes, including PDGF‑A in the LAPC4 cell model of
prostate cancer after ectopic overexpression of EGR‑1 (42).
Similarly, MIC‑1 seems to be positively regulated by EGR‑1 in
the LNCaP prostate cancer cell model (43). In contrast, there
is a lack of information for a potential regulatory function
of EGR‑1 for FASN in prostate cells or tissues, although our
computational analysis of genomic DNA up‑ and downstream
of the transcription initiation site indicates multiple EGR‑1
recognition sequences. Our own ectopic EGR‑1 overexpression and suppression data in RWPE‑1 cells confirms a positive
regulation of PDGF‑A, but resulted in a negative regulation of
MIC‑1. An obvious reason for this discrepancy is that RWPE‑1
represents a non‑cancerous pre‑malignant, as opposed to an
advanced cancer cell model, such as LNCaP (43). At the
experimental level, the use of reporter constructs for MIC‑1
activity (43) vs. qRT‑PCR using specific primers may also
have contributed to differences in the result. More importantly
however, our in vitro findings are supported by our extensive
in situ association studies in human tissues which are based
on factor correlations and their changes from disease‑free to
tumor‑adjacent to histologically abnormal tissues, thereby
confirming the presence of a field effect. In fact, using two data
acquisition modes our data show a positive association between
EGR‑1 and both PDGF‑A and FASN, which in turn support a
positive regulation. In contrast, our results suggest a negative
regulation of MIC‑1 by EGR‑1, which seemingly contradicts
our observation that both are upregulated in tumor‑adjacent
and cancerous prostate tissues when compared to disease‑free
controls (12). While the latter justifies the inclusion of MIC‑1
in the present study, this discrepancy indicates a more complex
regulatory network and warrants further investigations using
functional approaches in systems that reflect the complexity
of human tissues.
In summary, three principal conclusions can be drawn
from our findings. First, immunohistochemistry and immunofluorescence are techniques usually employed towards
qualitative assessment of protein expression and localization
in cells and tissues in a static manner. However, we show here
that using sophisticated quantitation methods, such as spectral
image acquisition, linear unmixing, and digital imaging developed in our previous reports (12,13), can deliver meaningful
indications of molecular associations in a physiologically
relevant in situ environment, even in the presence of high
heterogeneity. A related issue is the use of ROIs in quantitation. ROIs are often used to compensate for inequalities of
cell composition. Although our data show good congruency
between the whole‑image and ROI approaches for the most
part, it also cautions for care with respect to the number of
ROIs and their random and blinded placement. Second, our
study prompts for caution when comparing molecular association data generated in cell models with data stemming from
tissues. Although it can be argued that tissue studies are static
and compromised by sample heterogeneity, they can provide
meaningful indications of molecular regulations when coupled
with sophisticated data acquisition. Also, tissues are physiologically relevant, reflect better the complexity of cellular and
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molecular pathways influenced by the environment, and can
guide confirmatory studies in cell models. Third, we propose
EGR‑1 to be a key regulator of prostate field effect through
induction of pro‑proliferative and pro‑metabolic (PDGF‑A and
FASN, respectively) and suppression of pro‑apoptotic (MIC‑1)
factors. This is supported in particular by our comparative
data between disease‑free and tumor‑adjacent tissues (field
effect). Admittedly, while the positive regulation of PDGF‑A
and FASN by EGR‑1 can be easily acknowledged, its regulatory function for MIC‑1 seems less clear due to its concomitant
upregulation in tumor‑adjacent tissues (13). However, it is
important to note that these findings are not in disagreement,
as MIC‑1 regulation has been discussed to be complex (38,39).
This may be reflected in a complex in situ environment, such
as tissues, where many other factors may also exert their
regulatory effect. Future studies are warranted to test the
exact mechanisms of direct and/or indirect regulation under
physiological conditions, such as in animal models. Because it
is widely accepted that field effect represents a pre‑malignant
state, such knowledge may help develop targeted intervention
strategies preventing progression to cancer.
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